Kuehnle

August 19, 2025

Corbion and Kuehnle AgroSystems join forces to develop natural Astaxanthin from algae fermentation

Corbion, the Amsterdam-based global leader in sustainable ingredients, and US-based biotech company Kuehnle AgroSystems (KAS) have entered into a strategic partnership to develop and commercialize a high-quality, natural astaxanthin derived from non-GMO heterotrophic algae. Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms, including microalgae, salmon, and shrimp. It is widely recognized both for its human health benefits and as a key feed ingredient for salmon and other aquaculture species. Currently, most commercially available astaxanthin is either chemically synthesized for aquaculture use or derived from the phototrophic microalgae Haematococcus for human health applications. Corbion and KAS aim to provide a natural, algae-derived alternative produced through controlled fermentation of non-GMO, heterotrophic Haematococcus, the primary natural source of astaxanthin. The partnership will focus on developing an esterified form of astaxanthin, rich in the most bioavailable isomer, delivering superior antioxidant performance, enhanced stability, and fat solubility. Designed for both the human and animal nutrition markets, the product is particularly well-suited for nutraceuticals and aquaculture applications. By combining KAS’s advanced fermentation platform and proprietary non-GMO algae strains with Corbion’s industrial production capabilities, regulatory and go-to-market expertise, the two companies aim to bring this innovation to market at scale. “This partnership reinforces our commitment to sustainable, science-based solutions,” said Robert Jan de Voogd, General Manager, Algae Ingredients North America at Corbion. “KAS’ technology offers a strong foundation to deliver high-quality natural astaxanthin to customers looking for a clean-label alternative.” “We’re proud to collaborate with Corbion to scale our technology and make premium algae-derived antioxidants more accessible worldwide” said Claude Kaplan, CEO of KAS. Development and technical transfer have already begun, with further updates to follow as the project progresses.